ADC Development Solutions

ADC drugs, or Antibody-Drug Conjugates, are a class of pharmaceuticals formed by chemically linking small molecule drugs with biologically active antibodies. Throughout the ADC drug development process, key stages include target selection, antibody discovery and optimization, quality control, and clinical research.

With years of experience in protein, antibody, and ELISA kit development, CUSABIO can tailor products, services, and solutions to meet customer needs at various stages of ADC drug development.

Stable cell line construction refers to the integration of exogenous genes into recipient cells and their stable expression on the host cell membrane over the long term. Stable Cell Lines play a crucial role in biological research, widely used in applications such as recombinant protein and monoclonal antibody production, drug screening, and gene function studies.

With years of experience in protein expression research, CUSABIO has accumulated extensive experience in the development of Stable Cell Lines. We can effectively enhance the production capacity of Stable Cell Lines and improve experimental results. We now offer a range of stable cell line products targeting common drug targets, as well as one-stop services from gene sequence to stable line delivery for overexpression Stable Cell Lines and reporter gene cell lines.

DT3C is a recombinant protein composed of the diphtheria toxin (DT) without a receptor-binding domain and the C1, C2, and C3 (3C) domains of Streptococcus protein G. It is primarily employed for in vitro detection of the internalization efficiency of monoclonal antibodies by target cells.

Compared to common antibody internalization efficiency detection techniques such as acid buffer washout, mAb-ZAP method, pHrodo technology, etc., the DT3C recombinant protein assay for antibody internalization offers the advantages of simplicity, speed, and high detection efficiency.

CUSABIO has been dedicated to protein and antibody research and production for the past 16 years. We have successfully screened over 100 therapeutic antibody candidates for numerous pharmaceutical companies, with many progressing to the CMC or IND stages. Our excellent antigen preparation technology platform and extensive experience in antibody screening ensure that CUSABIO can provide you with a comprehensive one-stop solution from target identification to therapeutic antibody candidates, accelerating the entire drug development process.

In the Antibody Discovery and Optimization stage, techniques such as antibody molecule screening, pharmacokinetic analysis, and immunogenicity analysis often utilize ELISA methods due to their simplicity, speed, and high throughput capabilities. Leveraging years of experience in ELISA development and a robust quality control system, CUSABIO offers a comprehensive one-stop service from antigen design to ELISA kit production. Our advanced technological platform allows us to customize high-quality ELISA kits tailored to your specific requirements. These kits are designed for the detection and screening of specific antibodies, as well as antibody property assessment.

CUSABIO introduces specialized tools for preclinical and clinical stage antibody-drug research - anti-Payload antibodies (such as Anti DXD mAb，Anti MMAE，Anti Eribulin). These antibodies can be utilized for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, DAR value analysis, and evaluation of ADC drug efficacy.

Cytokine detection plays a pivotal role in the development of ADC drugs, particularly in the assessment of immunogenicity, pharmacodynamics research, and safety evaluation. CUSABIO has developed the IS series of Cytokine detection assay kits specifically for industrial clients, including pharmaceutical companies. Drawing on rich research and development experience and an independent research platform, we meticulously select high-performance raw materials, uphold stringent quality standards, and implement multiple quality control measures. Our products are suitable for a range of applications, including CRS detection, residual process material testing in drug manufacturing, pharmacokinetic experimental cell function evaluation, quality control in the development of cell therapy drugs, and pharmacological efficacy testing.

Through molecular biology cloning techniques, specific reporter genes (e.g., luciferase) are inserted into the chromosome of target cells. Following screening and cultivation, stable cell lines capable of expressing the reporter gene consistently are obtained. In the clinical research and development phase, stable cell lines play a crucial role in validating the functionality of ADCC (antibody-dependent cellular cytotoxicity) and ADCP (antibody-dependent cellular phagocytosis). These stable cell lines are utilized to assess the interaction between candidate drugs or biologics and immune cells, determining their ability to promote immune cell-mediated cytotoxicity or phagocytosis. By validating the ADCC/ADCP functionality of stable cell lines, the immunomodulatory effects of drugs can be evaluated, guiding the progression of preclinical development.

CUSABIO has years of experience in protein expression research and possesses extensive expertise in developing stable cell lines. We offer a comprehensive range of stable cell line products targeting common drug targets and provide one-stop services from gene sequencing to stable cell line delivery for overexpression stable cell lines and reporter gene cell lines, offering comprehensive solutions for stable cell line construction to recombinant protein production and beyond.

Due to the similarities between anti-idiotype antibodies and anti-drug antibodies (ADAs), anti-idiotype antibodies can serve as positive controls in immunogenicity analysis for the quantification of total anti-drug antibodies. Additionally, in pharmacokinetic (PK) and pharmacodynamic (PD) analyses of antibody drugs, anti-idiotype antibodies can be used to detect the levels of antibody drugs in the blood (free, bound, and total forms).

CUSABIO now offers services for the preparation of polyclonal rabbit anti-idiotype antibodies and monoclonal mouse anti-idiotype antibodies (anti-Fab, anti-ScFv). Leveraging our five major protein expression platforms and assay kit development platform, we can provide customers with a comprehensive service ranging from antigen preparation and Anti-idiotype Antibody development to the establishment of detection methods and the development of assay kits.